PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…
Press contact:Mollie MellowsPhone:+ 44 (0) 7342 709384E-mail: mollie.mellows@capgemini.com Capgemini unveils strategic AI framework to turn enterprise ambition into measurable business…
Planisware accelerates its development in Asia and announces the opening of an office in Seoul Paris, France, July 3, 2025…
A year defined by football.Since adidas’ inception, football has been intertwined with the brand’s story, and for the past several…
20 June 2025 - The International Olympic Committee (IOC) today published its 2024 Annual Report following its validation by the IOC membership.…
PARIS, June 19, 2025 /PRNewswire/ -- Saint-Gobain announces the next step in the expansion of its digital construction chemicals platform…
PARIS, June 18, 2025 /PRNewswire/ -- Lockheed Martin [NYSE: LMT] continues to revolutionize the future of tactical airlift with the C-130J Super…
SANTA CLARA, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Articul8, a leading enterprise GenAI company, today unveiled its next-generation multi-agent…
Press contact: Antara NandyTel.: +91 9674515119 Email: antara.nandy@capgemini.com Agentic AI integration set to accelerate this year among Gen AI early adopters Two…
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government…